Because no family should go through childhood cancer alone.
MEET CALEB

Neuroblastoma Warrior

For the last five years, 9-year-old Caleb has been battling Neuroblastoma, a rare childhood cancer that generally develops in the adrenal glands. From surgery to remove the tumors to countless rounds of chemotherapy and immunotherapy, the NCCS has supported Caleb and his family with the exhaustive travel costs from their Indiana home to treatment facilities in New York. Fortunately, Caleb’s scans have been much more promising in the last year, and he can enjoy just being a kid – baking, creating art and playing piano and ukulele.

Caleb has defied all odds and his family is deeply grateful for the support provided by the NCCS as they navigate the world of childhood cancer and work toward a healthy future.

MEET LILLIAN

Leukemia Warrior

Lillian was regarded by her parents as “the healthy child,” never having even a cold or runny nose. She was the picture of perfect health. That all changed when she was just shy of her 2nd birthday. The diagnosis was T-cell Lymphoblastic Leukemia, a fast-growing, aggressive cancer that turned her family’s world upside down.

In addition to addressing the cancer itself, treatment complications, side effects, immune system suppression, abnormal organ functions, loss of motor control and brittle bones are just some of the horrific ripple effects from her diagnosis that Lillian and her family have endured.

Lillian’s Mother shared her gratitude for support from the NCCS with travel assistance and educational and social support for Lillian and her family. “We are not sure anyone could have done this alone, and we cannot imagine having to survive this season without the love and support of others. NCCS is a tremendous blessing for people during times when the world is crashing in around you and helps shoulder some of the day-to-day struggles of food, gas and bills.”
Dear Friends,

Despite the challenges presented by the pandemic these last two years, The National Children’s Cancer Society (NCCS) continues to make great strides in our unwavering commitment that no family should go through childhood cancer alone. Whether across town or across the country, the “no matter what” approach of the NCCS ensures that we continue to provide the physical, financial and emotional resources for children battling cancer and their families.

One such child is 6-year-old Julia. At 18 months, Julia was diagnosed with bilateral retinoblastoma, cancer of the eye. Travelling from their home in Wisconsin to New York for regular, aggressive treatment, Julia’s family has faced many hardships over the last several years, including the significant impact of unexpected travel costs. Julia’s mother, Jessica, has expressed her heartfelt thanks for transportation assistance provided by the NCCS: “Saying thank you isn’t enough as we cannot even express in words our gratitude.” Today, Julia remains strong through ongoing treatments, and doctors are optimistic that she will lead a long, healthy life.

Julia’s story, along with so many others, serves as daily inspiration for the mission of NCCS. But we can’t do this work alone. With the support of our compassionate donors, we have assisted more than 46,000 children with cancer and distributed over $69,000,000 in financial assistance since the inception of the NCCS. Through our programs, we have reached children in 53 countries across the globe. To date, we have awarded 544 scholarships totaling nearly $2,000,000 to childhood cancer survivors, celebrating the hope of a bright future for our courageous young warriors.

If the last two years have taught us nothing else, it’s a spirit of perseverance—the same spirit that is reflected in the children and families that turn to us for help. Thank you for your continued support so that we can all provide a clear path for families navigating the world of childhood cancer, and most importantly, survivorship.

Please stay safe and well,

Mark Slocomb
Chairman of the Board

Mark Stolze
President and Chief Executive Officer
MISSION

The National Children’s Cancer Society (NCCS) provides emotional, financial and educational support to children with cancer, their families and survivors.

OVERVIEW

Since its inception, the NCCS has helped more than 46,000 children with cancer and their families by providing over $69 million in program distributions. The NCCS is a 501(c)(3) non-profit organization that is proud to meet all of the Better Business Bureau’s “Standards of Charity Accountability,” which includes a comprehensive, in-depth evaluation of charity governance, fundraising practices, solicitations and informational materials. The organization is also a Platinum Participant on GuideStar Exchange.

FY2021 REVENUE ALLOCATION

- Program Services: 85.12%
- Fundraising: 12.24%
- Management & General: 2.64%
Pediatric oncology nurses and social workers at treatment centers across the country refer families to the NCCS. One hundred seventy nine (179) treatment centers referred 1,578 families in need of assistance to the organization this fiscal year.

HOW WE HELP DURING TREATMENT

When a family is facing the tragedy of childhood cancer, the only thing they should have to focus on is getting their child well again. They shouldn’t be overwhelmed with the costs of just getting their child to treatment. But, how many of us have a savings plan in place for childhood cancer?

The NCCS offers two programs to ease the financial strain of a childhood cancer diagnosis. Our Transportation Assistance Fund alleviates some of the travel expenses incurred to get a child to treatment such as mileage, airfare and lodging when the best place for treatment is away from home.

The Emergency Assistance Fund provides an annual stipend to families who have a child who has been inpatient or away from home for an extended period of time. Assistance may be used for many daily expenses families face including mortgage payments, rent, utility bills and other treatment-related costs such as prescriptions and parking.

In addition to the financial impact of childhood cancer, the emotional toll can be devastating. Our Family Support Program helps ease the emotional strain that accompanies a childhood cancer diagnosis by providing an NCCS case manager who stands by a family’s side from diagnosis through survivorship. These dedicated individuals are specially trained to offer practical and emotional support during difficult times, educate parents and caregivers on how to best advocate for their child and provide referrals when needed.
THE FOLLOWING PEDIATRIC ONCOLOGY FACILITIES ACROSS THE U.S.

ALABAMA
Children’s of Alabama, Birmingham
St. Jude Affiliate Clinic at Huntsville Hospital for Women & Children, Huntsville
USA Children’s & Women’s Hospital, Mobile

ALASKA
Alaska Pediatric Oncology, Anchorage

ARIZONA
Banner Children’s at Desert, Mesa
Banner - University Medical Center, Tucson
Phoenix Children’s Hospital, Phoenix

ARKANSAS
Arkansas Children’s Hospital, Little Rock
Arkansas Children’s Northwest, Springdale

CALIFORNIA
Children’s Hospital Los Angeles, Los Angeles
CHOC Children’s, Orange
City of Hope, Duarte
Hoffmann Hospice & Palliative Care, Bakersfield
Kaiser Permanente, Fontana
Kaiser Permanente, Los Angeles
Kaiser Permanente, Ontario
Kaiser Permanente, Roseville
Kaiser Permanente, San Diego
Loma Linda University Children’s Health, Loma Linda
Loma Linda University Children’s Health, San Bernardino
Miller Children’s & Women’s Hospital, Long Beach
Rady Children’s Hospital, San Diego
Rady’s Proton Center, San Diego
Stanford Children’s Health - CA Pacific Medical Center, San Francisco
Stanford Children’s Health - Lucile Packard Children’s Hospital Stanford, Palo Alto
Sutter Medical Center, Sacramento
UC Davis Medical Center, Sacramento
UCSF Benioff Children’s Hospital, San Francisco
UCSF Benioff Children’s Hospital, Oakland
Valley Children’s Healthcare, Madera
Ventura County Medical Center, Ventura

COLOMBIA
Children’s Hospital Colorado, Aurora
Rocky Mountain Hospital for Children, Denver

CONNECTICUT
Connecticut Children’s, Hartford

DELAWARE
Nemours Children’s Hospital, Wilmington

DISTRICT OF COLUMBIA
Children’s National, Washington, DC

FLORIDA
AdventHealth for Children, Orlando
Ascension Sacred Heart Hospital, Pensacola
Bascom Palmer Eye Institute, Miami
Colisano Children’s Hospital - SW Florida, Ft. Myers
Jackson Health System, Miami
Joe DiMaggio Children’s Hospital, Hollywood
Johns Hopkins All Children’s Hospital, St. Petersburg
Johns Hopkins All Children’s Hospital, Tampa
Kids Cancer Foundation, Loxahatchee
Nemours Children’s Health, Jacksonville
Nemours Children’s Health System, Orlando
Nicklaus Children’s Hospital, Miami
Orlando Health Arnold Palmer Hospital for Children, Orlando
St. Joseph’s Children’s Hospital, Tampa
St. Mary’s Medical Center, West Palm Beach
Sylvester Comprehensive Cancer Center, Miami
Tampa General Hospital, Tampa
UF Health Shands Children’s Hospital, Gainesville
Wolfson Children’s, Jacksonville

GEORGIA
Children’s Healthcare of Atlanta, Atlanta
Children’s Healthcare of Atlanta at Egleston, Atlanta
Children’s Healthcare of Atlanta at Scottish Rite, Atlanta
Children’s Hospital of Georgia, Augusta
Emory Children’s Clinic, Atlanta
Memorial Health Dwaine & Cynthia Willett Children’s Hospital, Savannah
Atrium Health Navicent, Macon

ILLINOIS
 Advocate Children’s Hospital, Park Ridge
Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago
OSF HealthCare Children’s Hospital of Illinois, Peoria
St. Jude Midwest Affiliate, Peoria
UCHicago Medicine Comer Children’s, Chicago

INDIANA
Beacon Children’s Hospital, South Bend
Peyton Manning Children’s Hospital at Ascension St. Vincent, Indianapolis
Riley Hospital for Children, Indianapolis

IOWA
Blank Children’s Hospital, Des Moines
University of Iowa Stead Family Children’s Hospital, Iowa City

KANSAS
Wesley Children’s Hospital, Wichita

KENTUCKY
Norton Children’s Hospital, Louisville
UK HealthCare Kentucky Children’s Hospital, Lexington

LOUISIANA
Children’s Hospital, New Orleans
LSU Health, Shreveport
Ochsner Medical Center, New Orleans
Our Lady of the Lake Children’s Hospital, Baton Rouge
St. Jude Baton Rouge Affiliate Clinic, Baton Rouge

MARYLAND
Johns Hopkins Bloomberg School of Public Health, Baltimore
Johns Hopkins Children’s Center, Baltimore

MASSACHUSETTS
Baystate Medical Center, Springfield
Boston Children’s Hospital, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
UMass Memorial Health, Worcester

MICHIGAN
Bronson Children’s Hospital, Kalamazoo
Children’s Hospital of Michigan, Detroit
Helen DeVos Children’s Hospital, Grand Rapids
University of Michigan Medical Center, Ann Arbor

MINNESOTA
Mayo Clinic Hospital, St. Mary’s, Rochester
Mayo Eugenio Litta Children’s Hospital, Rochester
University of Minnesota Masonic Children’s Hospital, Minneapolis

MISSISSIPPI
University of Mississippi Medical Center, Jackson

MISSOURI
Barnes-Jewish Hospital, St. Louis
Children’s Hospital, St. Louis
Children’s Mercy, Kansas City
Mercy Clinic Children’s Cancer and Hematology, St. Louis
SSM Health Cardinal Glennon Children’s Hospital, St. Louis
St. Jude Affiliate Clinic, Springfield
Washington University School of Medicine, St. Louis

MONTANA
Montana Children’s Medical Center, Kalispell

NEBRASKA
Children’s Hospital & Medical Center, Omaha
Nebraska Medical Center, Omaha
**NEVADA**  
Renown Children’s Hospital, Reno  
Summerlin Hospital Medical Center, Las Vegas  
Sunrise Children’s Hospital, Las Vegas  

**NEW HAMPSHIRE**  
Children’s Hospital at Dartmouth-Hitchcock, Lebanon  

**NEW MEXICO**  
Presbyterian Hospital, Albuquerque  
UNM Children’s Hospital, Albuquerque  

**NEW YORK**  
Albany Medical Center Hospital, Albany  
Cohen Children’s Medical Center, New Hyde Park  
John R. Oishei Children’s Hospital, Buffalo  
Memorial Sloan Kettering Cancer Center, New York  
NYU Langone Health, New York  
NewYork-Presbyterian Morgan Stanley Children’s Hospital, New York  
Upstate Golisano Children’s Hospital, Syracuse  

**NORTH CAROLINA**  
Levine Children’s Hospital, Charlotte  
Mission Hospital, Asheville  
UNC Health, Chapel Hill  
Vidant Medical Center, Greenville  
Wake Forest Baptist Health, Winston-Salem  

**NORTH DAKOTA**  
Sanford Medical Center, Bismarck  
Sanford Roger Maris Cancer Center, Fargo  

**OHIO**  
Akron Children’s Hospital, Akron  
Cincinnati Children’s, Cincinnati  
Cleveland Clinic Children’s, Cleveland  
Dayton Children’s, Dayton  
Nationwide Children’s, Columbus  
ProMedica Russell J. Ebeid Children’s Hospital, Toledo  
University Hospitals Rainbow Babies and Children’s, Cleveland  

**OKLAHOMA**  
St. Francis Hospital, Tulsa  
Oklahoma Children’s Hospital, Oklahoma City  

**OREGON**  
Doernbecher Children’s Hospital, Portland  
Randall Children’s Hospital at Legacy Emanuel, Portland  

**PENNSYLVANIA**  
Children’s Hospital of Philadelphia, Philadelphia  
Lehigh Valley Reilly Children’s Hospital, Allentown  
Milton S. Hershey Medical Center, Hershey  
St. Christopher’s Hospital for Children, Philadelphia  
UPMC Children’s Hospital of Pittsburgh, Pittsburgh  

**RHODE ISLAND**  
Hasbro Children’s Hospital, Providence  

**SOUTH CAROLINA**  
Prisma Health Greenville Memorial Hospital, Greenville  
MUSC Children’s Health, Charleston  
Sanford Children’s Hospital Sioux Falls, Sioux Falls  

**TENNESSEE**  
Children’s Hospital at Erlanger, Chattanooga  
East Tennessee Children’s Hospital, Knoxville  
Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville  
Niswonger Children’s Hospital, Johnson City  
St. Jude Children’s Research Hospital, Memphis  
St. Jude Tri Cities Affiliate Clinic, Johnson City  
The Children’s Hospital at TriStar Centennial, Nashville  
Vanderbilt University, Nashville  

**TEXAS**  
Children’s Medical Center, Dallas  
Children’s Memorial Hermann Hospital, Houston  
Cook Children’s Medical Center, Ft. Worth  
Covenant Medical Center, Lubbock  
Dell Children’s Medical Center of Central Texas, Austin  
Driscoll Children’s Hospital, Corpus Christi  
El Paso Children’s Hospital, El Paso  
Baylor Scott & White McLane Children’s, Temple  
Methodist Children’s Hospital, San Antonio  
Texas Children’s Hospital, Houston  
Texas Tech University Health Sciences Center, Amarillo  
The University of Texas MD Anderson Cancer Center, Houston  

**VERMONT**  
The University of Vermont Children’s Hospital, Burlington  

**VIRGINIA**  
Children’s Hospital of Richmond at VCU, Midlothian  
Children’s Hospital of The King’s Daughters, Norfolk  
University Hospital, Charlottesvile  
Virginia Commonwealth University, Richmond  

**WASHINGTON**  
Mary Bridge Children’s, Tacoma  
Providence Sacred Heart Medical Center & Children’s Hospital, Spokane  
Seattle Children’s, Seattle  

**WEST VIRGINIA**  
CAMC Women and Children’s Hospital, Charleston  
West Virginia University Medicine Children’s, Morgantown  

**WISCONSIN**  
Children’s Wisconsin, Milwaukee  
American Family Children’s Hospital, Madison
Beyond the Cure is the NCCS survivorship program which prepares survivors and their families for life after cancer.

One of the largest issues survivors face are post–treatment physical and cognitive issues known as “late effects.” Most survivors will experience one or more late effects in their lifetime which are caused more from the treatment than the disease, itself.

Our Late Effects After Treatment Tool (LEATT) is a valuable resource that provides survivors with a private, customized online assessment of potential late effects based on their diagnosis and treatment. The assessment includes important information that can be shared with a survivor’s healthcare team throughout their lifetime.

The LEATT was developed in collaboration with NCCS board member, Robert Hayashi, MD, Professor of Pediatrics, Director, Late Effects Clinic, St. Louis Children’s Hospital/Washington University School of Medicine.

Beyond the Cure also awards college scholarships to childhood cancer survivors through the Beyond the Cure Ambassador Scholarship Program. 58 college-bound childhood cancer survivors around the country received scholarships totaling $203,000 during FY2021.

First-time applicants are required to submit an essay addressing how cancer has affected their lives and future, as well as how they plan to give back to the childhood cancer community.

More than $1.8 million has been distributed to survivors to help them achieve their educational goals. The NCCS is deeply grateful to Centene Corporation and the Engelhardt Family Foundation for their generous support of the program.

SURVIVORSHIP CONFERENCES

Beyond the Cure co-sponsors survivorship conferences with long term follow–up clinics across the country. Due to the COVID-19 pandemic, only one conference was held in FY21 at Advocate Children’s Hospital in Chicago, IL.

EDUCATIONAL PUBLICATIONS

The organization distributed 1,908 free publications during FY2021. The NCCS publication library includes an activity book that provides a creative outlet for patients to learn about themselves and their cancer treatment, coloring books for young children, information for college-bound survivors and in–depth guides for both survivors and their families.
Most childhood cancers can be cured if treated promptly and effectively. However, eighty percent of children diagnosed with cancer in low- and middle-income countries will lose their battle due to a lack of information, early detection and access to effective treatment.

The Michele Hertlein Global Outreach Program addresses the inadequate or nonexistent medical care for children with cancer in underserved countries around the globe, at absolutely no cost to the family.

Over $21 million in donated pharmaceuticals and medical supplies were sent free of charge to 10 pediatric oncology treatment centers, totaling 42 hospitals and their associated clinics in 20 countries this fiscal year.

Since its inception, this unique program has distributed in excess of $438 million in donated pharmaceuticals to 77 facilities in 53 countries, helping to save the lives of an estimated 171,000 children with cancer worldwide.

The program’s namesake, Michele Hertlein, worked tirelessly for 24 years to secure and ship donated pharmaceuticals and medical supplies to pediatric treatment centers around the world. Michele lost her own 10-year battle with cancer in 2020 and is dearly missed. She leaves a legacy of compassionate, relentless pursuit to support children and their families in their battle against childhood cancer—NO MATTER WHAT.
INDEPENDENT AUDITORS' REPORT

Board of Directors
The National Children's Cancer Society, Inc.
St. Louis, Missouri

We have audited the accompanying financial statements of The National Children's Cancer Society, Inc. (a nonprofit organization), which comprise the statement of financial position as of September 30, 2021, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the financial statements referred to above present fairly in all material respects the financial position of The National Children's Cancer Society, Inc., as of September 30, 2021, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

CliftonLarsonAllen LLP

St. Louis, Missouri
January 4, 2022

CLA is an independent member of Nexia International, a leading, global network of independent accounting and consulting firms. See nexia.com/member-firm-disclaimer for details.
STATEMENT OF FINANCIAL POSITION  
SEPTEMBER 30, 2021

ASSETS

CURRENT ASSETS
Cash $ 521,961
Accounts Receivable, Net 266,995
Employee Retention Credit Receivable 363,906
Inventory 16,882
Prepaid Expenses and Other Assets 31,986
Total Current Assets 1,201,742

NONCURRENT ASSETS
Investments 4,875,096
Property and Equipment, Net 5,172
Total NonCurrent Assets 4,880,268

Total Assets $ 6,082,010

LIABILITIES AND NET ASSETS

CURRENT LIABILITIES
Accounts Payable $ 1,059,539
Annuities Payable 17,240
Accrued Expenses 127,975
Uearned Revenue 7,896
Line of Credit 413,288
Total Current Liabilities 1,625,938

LONG-TERM LIABILITIES
Annuities Payable 101,381
Total Long-Term Liabilities 101,381

NET ASSETS
Without Donor Restrictions 3,661,074
With Donor Restrictions 693,617
Total Net Assets 4,354,691

Total Liabilities and Net Assets $ 6,082,010

STATEMENT OF ACTIVITIES  
YEAR ENDED SEPTEMBER 30, 2021

PUBLIC SUPPORT AND REVENUE

Without Donor Restrictions  With Donor Restrictions  Total
Contributions $ 7,582,341 $ -  $ 7,582,341
List Rental Income 65,443 -  65,443
Event Revenue 143,637 -  143,637
Less Direct Costs of Events (5,427) - (5,427)
In-Kind Contributions 21,663,575 -  21,663,575
Investment Income 766,801 100,249 867,050
Employee Retention Credit Income 363,906 -  363,906
Paycheck Protection Plan Forgiveness 554,260 -  554,260
Net Assets Released from Restrictions - Satisfaction of Program Restrictions 15,113 (15,113) -
Total Public Support and Revenue 31,149,649 85,136 31,234,785

EXPENSES
Program Services:  
Division of Patient and Family Services 23,843,608 -  23,843,608
Supplemental Family Support 1,177,069 -  1,177,069
Public Information and Education 259,396 -  259,396
Total Program Services 25,280,073 -  25,280,073

Supporting Services:  
Management and General 783,487 -  783,487
Fundraising 3,636,637 -  3,636,637
Total Supporting Services 4,420,124 -  4,420,124
Total Expenses 29,700,197 -  29,700,197

OTHER INCOME (EXPENSE)
Change in Value of Annuities (8,457) -  (8,457)

NET CHANGE IN NET ASSETS 1,440,995 85,136 1,526,131
Net Assets - Beginning of Year 2,220,079 608,481 2,828,560

NET ASSETS - END OF YEAR $ 3,661,074 $ 693,617 $ 4,354,691

See accompanying Notes to Financial Statements.
CASH FLOWS FROM OPERATING ACTIVITIES

<table>
<thead>
<tr>
<th>Division of Patient and Family Services</th>
<th>Supplemental Family Support</th>
<th>Public Information and Education</th>
<th>Management and General</th>
<th>Fundraising</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aid Grants</td>
<td>$21,663,575</td>
<td>$1,039,986</td>
<td>$ -</td>
<td>$ -</td>
<td>$22,703,561</td>
</tr>
<tr>
<td>Production Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>461,329</td>
<td>3,265,220</td>
</tr>
<tr>
<td>Family Services and Education</td>
<td>1,330,957</td>
<td>1,240</td>
<td>2,346</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Salary Expense</td>
<td>373,630</td>
<td>74,446</td>
<td>140,869</td>
<td>174,548</td>
<td>169,417</td>
</tr>
<tr>
<td>Professional Services</td>
<td>86,100</td>
<td>17,155</td>
<td>32,462</td>
<td>40,223</td>
<td>39,040</td>
</tr>
<tr>
<td>Insurance</td>
<td>79,690</td>
<td>15,879</td>
<td>30,046</td>
<td>37,229</td>
<td>36,134</td>
</tr>
<tr>
<td>In-Kind Program Shipping</td>
<td>166,811</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>166,811</td>
</tr>
<tr>
<td>Rent and Utilities</td>
<td>38,275</td>
<td>7,626</td>
<td>14,431</td>
<td>17,881</td>
<td>17,355</td>
</tr>
<tr>
<td>Other Expenses</td>
<td>36,948</td>
<td>5,840</td>
<td>11,050</td>
<td>18,010</td>
<td>16,754</td>
</tr>
<tr>
<td>Payroll Taxes</td>
<td>29,310</td>
<td>5,840</td>
<td>11,050</td>
<td>13,692</td>
<td>13,290</td>
</tr>
<tr>
<td>Cause Related Marketing</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>62,277</td>
</tr>
<tr>
<td>Retirement</td>
<td>18,682</td>
<td>3,722</td>
<td>7,044</td>
<td>8,728</td>
<td>8,471</td>
</tr>
<tr>
<td>Telephone</td>
<td>7,232</td>
<td>1,441</td>
<td>2,727</td>
<td>3,378</td>
<td>3,279</td>
</tr>
<tr>
<td>Postage, Shipping, and Handling</td>
<td>4,641</td>
<td>925</td>
<td>1,750</td>
<td>2,168</td>
<td>2,104</td>
</tr>
<tr>
<td>Equipment Rental</td>
<td>3,109</td>
<td>619</td>
<td>1,172</td>
<td>1,452</td>
<td>1,401</td>
</tr>
<tr>
<td>Office Supplies and Services</td>
<td>1,889</td>
<td>376</td>
<td>712</td>
<td>3,789</td>
<td>856</td>
</tr>
<tr>
<td>Direct Costs of Events</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5,427</td>
</tr>
<tr>
<td>Depreciation Expense</td>
<td>1,492</td>
<td>297</td>
<td>563</td>
<td>697</td>
<td>677</td>
</tr>
<tr>
<td>Meetings and Travel</td>
<td>777</td>
<td>155</td>
<td>293</td>
<td>383</td>
<td>353</td>
</tr>
<tr>
<td>Shipping and Procurement</td>
<td>490</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>490</td>
</tr>
<tr>
<td>Total</td>
<td>23,843,608</td>
<td>1,177,069</td>
<td>259,396</td>
<td>783,487</td>
<td>3,642,064</td>
</tr>
<tr>
<td>Less: Direct Costs of Events</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(5,427)</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>$23,843,608</td>
<td>$1,177,069</td>
<td>$259,396</td>
<td>$783,487</td>
<td>$3,636,637</td>
</tr>
</tbody>
</table>

CASH FLOWS FROM INVESTING ACTIVITIES

| Purchases of Property and Equipment    | (3,973)                    |
| Proceeds from Sale of Investments     | 1,398,206                  |
| Purchases of Investments              | (1,087,870)                |
| Net Cash Provided by Investing Activities | 306,383                  |

CASH FLOWS FROM FINANCING ACTIVITIES

| Net Proceeds on Line of Credit         | 160,661                    |
| Proceeds from Paycheck Protection Program Loan | 259,130                  |
| Net Cash Provided by Financing Activities | 419,791                  |

NET CHANGE IN CASH

<table>
<thead>
<tr>
<th>Cash - Beginning of Year</th>
<th>342,329</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET CHANGE IN CASH</td>
<td>179,632</td>
</tr>
</tbody>
</table>

CASH - END OF YEAR

| $521,961 |
NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations
The National Children’s Cancer Society, Inc. (the Organization) was incorporated in November 1987 to serve children with cancer and their families. Program services are categorized as follows: Division of Patient and Family Services, Supplemental Family Support and Public Information and Education. The Organization provides a Family Support Program, Transportation Assistance Fund, and Emergency Assistance Fund for families with children in treatment, a Beyond the Cure Program for cancer survivors, and a Global Outreach Program.

Basis of Presentation
Financial statement presentation follows the recommendations of the Financial Accounting Standards Board (FASB). The Organization is required to report information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions. As of September 30, 2021, the Organization had $693,617 in net assets with donor restrictions.

Basis of Accounting
The financial statements of the Organization have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

Concentration of Credit Risk
The majority of the Organization’s cash and cash equivalents are maintained at three banks. The bank provides a maximum protection under regulations issued by the Federal Deposit Insurance Corporation. At September 30, 2021, deposits at the bank in excess of federally insured limits were $132,414.

Cash and Cash Equivalents
Cash includes demand deposits and highly liquid financial instruments purchased with original maturities of three months or less. The carrying amount of cash equivalents approximates fair value.

Certain cash balances are required to be held in separate bank accounts in accordance with contractual arrangements.

Accounts Receivable
Receivables consist of amounts due to the Organization related to the direct mail, telemarketing, and royalty programs. Management writes off receivables when it determines that an amount will not be collected and considers all receivables at September 30, 2021 to be collectible. Therefore, no allowance for doubtful accounts is recorded at September 30, 2021. All receivables are considered current at September 30, 2021; therefore, no discount has been recorded.

Investments
In accordance with accounting standards, investments in marketable securities with readily determinable fair values are reported at fair value in the statement of financial position. Unrealized gains and losses are included in the statement of activities.

Inventory
Inventory consists of program literature and patient and family service items and is stated at the lower of cost or net realizable value, determined on the first-in, first out method.

Property and Equipment
Furniture and equipment is recorded at cost. Maintenance and repairs are charged to operations when incurred. Betterments and renewals in excess of $500 are reviewed individually by management and are capitalized.

Donations of furniture and equipment are recorded as support at their estimated fair value. Such donations are reported as without donor restricted support unless the donor has restricted the donated asset to a specific purpose.

Depreciation and amortization are provided on a straight-line basis over the following periods:

<table>
<thead>
<tr>
<th>Asset Type</th>
<th>Useful Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furniture and Fixtures</td>
<td>7 Years</td>
</tr>
<tr>
<td>Equipment</td>
<td>3 to 7 Years</td>
</tr>
<tr>
<td>Software</td>
<td>3 Years</td>
</tr>
<tr>
<td>Leasehold Improvements</td>
<td>7 Years</td>
</tr>
</tbody>
</table>

Compensated Absences
Employees of the Organization are entitled to paid vacation days depending on length of service. Amounts accrued for compensated absences are included in accounts payable and accrued expenses in the accompanying statement of financial position.
NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Contributions
In accordance with accounting standards, contributions received by the Organization are recorded as with donor restriction or without donor restriction support, depending on the existence and nature of any donor restrictions. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Contributions that are restricted by the donor are reported as increases in net assets without donor restrictions if the restrictions expire within the fiscal year the contributions are recognized.

Annuities Payable
Annuities payable represents an annuity obligation for gift annuities received by the Organization. Gift annuities provide for payment to named annuitants over their lifetimes. The payment is guaranteed by the Organization through an agreement. An annuities payable liability is recorded until the projected termination of the annuity payment obligation based upon the present value of the expected payments over the life expectancy of the annuitants. The current annuity values are valued at fair value. The Organization reviews AFR in determining the discount rate to apply for the present value calculation. A discount rate of 1.0% was applied to determine the liability at September 30, 2021. Fair value at September 30, 2021 is $263,257, while the recorded liability is $118,621.

Unearned Revenue
Unearned revenue consists of payments received in advance that relate to donated items to be sold by a third party in a future period and are deferred and recognized as revenue in the period earned.

Use of Estimates
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of support, revenues, and expenses during the reporting period, including grant and contract revenues subject to review by applicable funding agencies. Accordingly, actual results could differ from those estimates.

Fair Value Measurements
The Organization measures fair value using a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability. Inputs may be observable or unobservable and refer broadly to the assumptions that market participants would use in pricing the asset or liability. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the reporting entity’s own assumptions about the assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

The objective of a fair value measurement is to determine the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). Accordingly, the fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The Organization may use valuation techniques consistent with the market, income and cost approaches to measure fair value.

The inputs used to measure fair value are categorized into the following three categories:

- **Level 1** - Inputs that reflect unadjusted quoted prices in active markets for identical investments, such as stocks, corporate and government bonds that the Organization has the ability to access as of the measurement date.
- **Level 2** - Inputs, other than quoted prices, that are observable for the asset or liability either directly or indirectly, including inputs from markets that are not considered to be active.
- **Level 3** - Inputs that are unobservable. Unobservable inputs reflect the Organization’s own assumptions about the factors market participants would use in pricing an investment, and is based on the best information available in the circumstances.

Following is a description of the valuation methodologies and inputs used for assets measured at fair value on a recurring basis and recognized in the accompanying statements of financial position, as well as the general classification of such assets and liabilities pursuant to the valuation hierarchy.

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities include money market mutual funds, certain mutual funds, and equities. If quoted market prices are not available, then fair values are estimated by using pricing models or quoted prices of securities...
NOTE 1  ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

with similar characteristics. These Level 2 securities include mortgaged and asset-backed securities, corporate
and municipal bonds, U.S. government agencies, hedge funds and managed futures. Inputs used to value Level 2
securities include interest rates for similar debt securities, Treasury obligations with similar maturities and net asset
values provided by funds is utilized as a practical expedient. In certain cases where Level 1 or Level 2 inputs are
not available, securities are classified within Level 3 of the hierarchy and include hedge funds. The net asset value
(or its equivalent) provided by the fund is utilized, as a practical expedient, to determine fair value of these Level 3
investments. The funds are classified as Level 3 if they may not be redeemable in the short-term.

Any transfers in and out of Level 1 (quoted market prices), Level 2 (other significant observable inputs) and Level 3
(significant unobservable inputs) are recognized on the period ending date.

Development Costs
The Organization periodically incurs substantial costs for the continued development of a contributor list. In
accordance with U.S. GAAP, the Organization recognizes these costs as they are incurred against operations, even
though the contributor lists are expected to provide significant benefit to future periods.

Functional Expense Allocations
The costs of providing various program and other activities of the Organization have been summarized on a
functional basis in the statement of functional expenses. Expenses are charged to program services, fundraising
or management and general based on actual costs incurred by the program or supportive service, as well as on
management’s best estimate of time spent in the functional expense categories. Management and general expenses
include those expenses that are not directly identifiable with any other specific section but provide for the overall
support and direction of the Organization.

Tax Status
The Organization qualifies as a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code.
However, the Organization is liable for federal income taxes on certain unrelated business income.

Management analyzed the tax positions taken by the Organization and concluded that, as of September 30, 2021,
there were no uncertain tax positions taken or are expected to be taken. Accordingly, no interest or penalties related
to uncertain tax positions have been accrued in the accompanying financial statements.

Change in Accounting Principle
In May 2014, FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers
(Topic 606). Subsequent to May 2014, the FASB has issued six ASUs to clarify certain matters related to Topic 606.
Topic 606 requires the recognition of revenue when promised goods or services are transferred to customers in
an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or
services. The updates address the complexity and understandability of revenue recognition and provide sufficient
information to enable financial statements users to understand the nature, amount, timing, and uncertainty of
revenue and cash flows arising from contracts with customers.

These financial statements reflect the application of ASC 606 guidance beginning in the year ended September
30, 2021. No cumulative-effect adjustment in net assets was recorded as the adoption of ASU 2014-09 did not
significantly impact the Organization’s reported historical revenue.

Subsequent Events
In preparing these financial statements, the Organization has evaluated events and transactions for potential
recognition or disclosure through January 4, 2022, the date the financial statements were available to be issued.

NOTE 2  LIQUIDITY AND AVAILABILITY
Financial assets available for general expenditure, this is, without donor or other restrictions limiting their use, within
one year of the statement of financial position date, comprise the following at September 30, 2021:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$ 521,961</td>
</tr>
<tr>
<td>Accounts Receivable</td>
<td>266,995</td>
</tr>
<tr>
<td>Investments</td>
<td>4,875,096</td>
</tr>
<tr>
<td>Total Current Financial Assets</td>
<td>5,664,052</td>
</tr>
<tr>
<td>Financial Assets Available to Meet Cash Needs for General Expenditures Within One Year</td>
<td>$ 4,970,435</td>
</tr>
</tbody>
</table>
NOTE 3 INVESTMENTS
Investments consist of the following at September 30, 2021:

<table>
<thead>
<tr>
<th>Investments</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government and Agency Securities</td>
<td>$547,561</td>
</tr>
<tr>
<td>Equity Securities</td>
<td>$3,365,008</td>
</tr>
<tr>
<td>Mutual Funds</td>
<td>$962,527</td>
</tr>
<tr>
<td><strong>Total Investments</strong></td>
<td><strong>$4,875,096</strong></td>
</tr>
</tbody>
</table>

Investment return for the year ended September 30, 2021 is summarized as follows:

<table>
<thead>
<tr>
<th>Investment Return</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest and Dividend Income</td>
<td>$84,464</td>
</tr>
<tr>
<td>Unrealized Gain on Equity Securities</td>
<td>$486,236</td>
</tr>
<tr>
<td>Realized Gain on Sale of Investments</td>
<td>$296,350</td>
</tr>
<tr>
<td><strong>Total Investment Gain</strong></td>
<td><strong>$867,050</strong></td>
</tr>
</tbody>
</table>

NOTE 4 FAIR VALUE MEASUREMENTS
The Organization uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. For additional information on how the Organization values all other assets and liabilities refer to Note 1 – Organization and Summary of Significant Accounting Policies.

The following table presents the fair value hierarchy for the balances of the assets of the Organization measured at fair value on a recurring basis as of September 30, 2021:

<table>
<thead>
<tr>
<th>Fair Value Hierarchy</th>
<th>Total</th>
<th>(Level 1)</th>
<th>(Level 2)</th>
<th>(Level 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government and Agency Bonds</td>
<td>$547,561</td>
<td>$</td>
<td>$547,561</td>
<td>$</td>
</tr>
<tr>
<td>Equity Securities</td>
<td>$3,365,008</td>
<td>$3,365,008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mutual Funds</td>
<td>$962,527</td>
<td>$962,527</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$4,875,096</strong></td>
<td><strong>$4,327,535</strong></td>
<td><strong>$547,561</strong></td>
<td></td>
</tr>
</tbody>
</table>

NOTE 5 NET ASSETS WITH DONOR RESTRICTIONS
Net assets with donor restrictions at September 30, 2021 consist of:

<table>
<thead>
<tr>
<th>Restriction</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose Restriction For Cancer Treatment in Minnesota</td>
<td>$693,617</td>
</tr>
</tbody>
</table>

Assets released from restrictions for the year ended September 30, 2021 are as follows:

<table>
<thead>
<tr>
<th>Satisfaction of Purpose Restriction</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$15,113</td>
</tr>
</tbody>
</table>

NOTE 6 PROPERTY AND EQUIPMENT
Property and equipment consists of the following at September 30, 2021:

<table>
<thead>
<tr>
<th>Property and Equipment</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furniture and Fixtures</td>
<td>$17,878</td>
</tr>
<tr>
<td>Equipment</td>
<td>$50,012</td>
</tr>
<tr>
<td>Software</td>
<td>$298,611</td>
</tr>
<tr>
<td>Leasehold Improvements</td>
<td>$6,800</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>373,301</strong></td>
</tr>
<tr>
<td>Less: Accumulated Depreciation</td>
<td>$(368,129)</td>
</tr>
<tr>
<td>Property and Equipment</td>
<td>$(5,172)</td>
</tr>
</tbody>
</table>

Depreciation expense was $3,726 for the year ended September 30, 2021.
NOTE 7  ALLOCATION OF JOINT COSTS

The Organization combines the costs of its joint activities that combine fundraising appeals with other functions, and allocates those costs to their functional classifications. Such costs include printing, caging, donor search, public information, computer expenses, list development, direct mail expense, postage, and production fees. The physical units method is used to allocate these costs. This allocation process is based on lines of print from the documents and scripts used in the joint activities. Each line of print is analyzed and a determination is made as to its purpose. The number of lines for each objective is totaled and weighed against the total number of lines in the document as well as the frequency of use of the document.

The Organization’s total joint costs incurred and functional classifications for the year ended September 30, 2021 are as follows:

<table>
<thead>
<tr>
<th>Functional Classification:</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$1,334,543</td>
</tr>
<tr>
<td>Management and General</td>
<td>461,329</td>
</tr>
<tr>
<td>Fundraising</td>
<td>3,265,220</td>
</tr>
<tr>
<td><strong>Total Joint Costs</strong></td>
<td><strong>$5,061,092</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of Activity:</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Mail</td>
<td>$5,056,507</td>
</tr>
<tr>
<td>Telemarketing</td>
<td>4,585</td>
</tr>
<tr>
<td><strong>Total Joint Costs</strong></td>
<td><strong>$5,061,092</strong></td>
</tr>
</tbody>
</table>

The Organization’s total joint costs incurred and functional classifications for the year ended September 30, 2021 are as follows:

The Organization follows standards for accounting and reporting costs of joint activities that combine fundraising appeals with other functions including definitions for the criteria of purpose, audience, and content. In accordance with the standard, the compensation structure of the joint activity is considered, as well as the target audience of the activity and the content of the information conveyed. If any of the criteria of purpose, audience, and content is not met, all costs of the joint activity are considered fundraising.

NOTE 8  OPERATING LEASES

The Organization leases office space, office equipment, and a vehicle under operating leases. The Organization’s office lease has escalating lease payments ranging from $4,760 to $5,170 per month over the remaining term of the lease expiring September 30, 2023.

The future minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of September 30, 2021 are as follows:

<table>
<thead>
<tr>
<th>Year Ending September 30,</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>113,097</td>
</tr>
<tr>
<td>2023</td>
<td>107,037</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$220,134</strong></td>
</tr>
</tbody>
</table>

Total rental expense under operating leases with a term in excess of one month was $68,256 for the year ended September 30, 2021.

NOTE 9  RETIREMENT PLAN

The Organization has a defined contribution retirement plan covering substantially all of its employees. Contributions to the plan and related expenses were $46,647 for the year ended September 30, 2021.

NOTE 10  AID GRANTS

The Organization receives and disburses both cash and in-kind grants to individuals and organizations. During the year ended September 30, 2021, the Organization recognized and disbursed $21,663,575 of in-kind contributions, consisting primarily of pharmaceuticals and medical supplies. The grants were recorded at their estimated fair value in the financial statements based on valuations provided by the donors, primarily manufacturers or distributors, and comparison with other industry sources.

NOTE 11  LINE OF CREDIT

The Organization has a Loan Management Account Agreement with a bank which allows the Organization to borrow under a revolving line of credit arrangement. Available credit is subject to borrowing base limitations determined by the bank based upon the market value of pledged securities. Advances under the agreement can be made under variable rate, fixed rate and term advances agreed upon at the time of the advance. Advances are due upon demand. Investments held by Merrill Lynch are pledged as collateral. Available credit under the agreement at September 30, 2021 was $2,779,376. At September 30, 2021, borrowings under the agreement were $413,288, all in principal. The balance is subject to interest at a variable rate of LIBOR plus the spread. The interest rate as of September 30, 2021 is 2.09%.

Cash paid for interest on the line of credit was $7,394 for the year ended September 30, 2021.
NOTE 12 PAYROLL PROTECTION PROGRAM LOAN

On April 13, 2020, and January 20, 2021, the Organization received loans from Triad Bank totaling $295,130 and $259,130 respectively, to fund payroll, rent, utilities, and interest on mortgages and existing debt through the Paycheck Protection Program (the PPP Loan). The PPP Loans bear interest at a fixed rate of 1.0% per annum, have terms of two years, and are unsecured and guaranteed by the U.S. Small Business Administration (SBA). Payment of principal and interest is deferred until the date on which the amount of forgiveness is remitted by the SBA to the lender or, if the Organization fails to apply for forgiveness within 10 months after the covered period, then payment of principal and interest shall begin on that date. These amounts are subject to forgiveness based on compliance with program requirements and approval by the SBA. The covered period from April 17, 2020 to October 2, 2020 for the first loan and January 20, 2021 to July 6, 2021 for the second loan is the time that the business had to spend their PPP Loan funds.

The Organization is following ASC 470, Debt, to account for the initial receipts related to the PPP Loans. On November 2, 2020, the SBA processed the Organization’s first PPP Loan forgiveness application and notified Triad Bank the PPP Loan qualified for full forgiveness. Loan proceeds were received by the bank from the SBA on this date. Then, on August 10, 2021, SBA processed the second PPP Loan and notified Triad bank the PPP Loan qualified for full forgiveness. Therefore, the Organization was legally released from the debt of both loans and the loan forgivenesses have been recorded as a gain on extinguishment of debt, which is included in other income during the year ended September 30, 2021.

The SBA may review funding eligibility and usage of funds for compliance with program requirements based on dollar thresholds and other factors. The amount of liability, if any, from potential noncompliance cannot be determined with certainty; however, management is of the opinion that any review will not have a material adverse impact on the Organization’s financial position.

NOTE 13 EMPLOYEE RETENTION CREDIT

Grants from the government are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Association complied with the conditions of Employee Retention Credit (ERC) funding in the amount of $363,906 in compliance with the program.

Grants related to this program are classified as other income and grants receivable. The Association recognized $363,906 of employee retention credits and grants receivable related to performance requirements being met and costs being incurred in compliance with the program during the year ended September 30, 2021.

NOTE 14 RELATED PARTY TRANSACTIONS

During the year ended September 30, 2021, the Organization received $52,058 in contributions from various members of the board of directors (Directors). In addition, during the year ended September 30, 2021, the Organization received $75,000 from companies in which Directors serve as a director or officer. At September 30, 2021, there were no receivables from related parties. The Organization also did not receive any In-Kind gifts from various board members of the board of directors during the year ended September 30, 2021.

One of the asset custodians is a financial institution for which a member of the board of the National Children’s Cancer Society is an officer. The amount paid to the asset custodian during the year ended September 30, 2021 totaled $54,121. The board member was not directly compensated for services provided.

NOTE 15 RISKS AND UNCERTAINTIES

The Organization’s assets include investments in various securities which, in general, are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is reasonably possible that changes in risks in the near term would materially affect the amounts reported in the balance sheets and the statements of activities.

The World Health Organization declared the spread of Coronavirus Disease (COVID–19) a worldwide pandemic. The COVID–19 pandemic is having significant effects on global markets, supply chains, businesses and communities. Specific to the Organization, COVID–19 may impact various parts of its 2022 operations and financial results. Management believes the organization is taking appropriate actions to mitigate the negative impact. However, the full impact of COVID–19 is unknown and cannot be reasonably estimated as these events are still developing.
BOARD OF DIRECTORS

Mark Slocomb
Chairman / Vice Chairman

Scott Stringer
Vice Chairman

Sue Engelhardt
Secretary/Treasurer

Mark Stolze
President & CEO

Dr. Timothy Dilg

Michael Gallagher

Tom Guebert

Scott Hammack

Robert Hayashi, M.D.

Brad Hermann

Brad Loos

Jeff Michalski, M.D.

Harry Mueller

Allen T. Smith